Discharge Coordinator Intervention in Patients With Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Other: ControlOther: Coordinated discharge
- Registration Number
- NCT01225627
- Lead Sponsor
- The University Clinic of Pulmonary and Allergic Diseases Golnik
- Brief Summary
This is a single-centre randomized controlled clinical trial which will enroll COPD patients in Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage II-IV, hospitalized due to acute exacerbation. Patients will be randomised in a 1:1 fashion to intervention group, which will have care organized by discharge coordinator, and control group which will receive care as usual. The primary endpoint of this study is time to hospitalization due to COPD worsening. Data will be collected at baseline, at the time of hospital discharge, and at following time-points after the hospital discharge: 48 hours, 7-10 days, 30 days, 90 days, and 180 days.
- Detailed Description
This is a single-centre randomized controlled clinical trial to assess the effectiveness of discharge coordinator intervention compared to care as usual in patients with COPD.
The study is being conducted at University Clinic of Pulmonary and Allergic Diseases Golnik, Slovenia. Patients with suspicion of acute exacerbation of COPD will be screened at admission when they will be informed about study details. After explanations of concerns and questions that they might have, a signed informed consent will be collected. During 48 hours, patients will be included according to their eligibility. Main inclusion criteria are COPD stage II-IV according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines, ability to perform phone contacts and availability for home visits. Patients will be excluded if in unstable or terminal stage of disease other than COPD, if they will die during hospitalization, or if unable to follow the study protocol.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 253
- age >35 years
- acute exacerbation of COPD stage II-IV
- residence in the geographical area linked to the study hospital
- ability to communicate
- give written informed consent
- diagnosis of cognitive impairment
- unstable or terminal disease other than COPD
- withdrawal of written informed consent before discharge
- inability of phone contact
- death during hospitalisation
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Control Control Patients in control group will be managed by attending physician, primary care physician, and/or pneumologist in accordance with established clinical practice. Coordinated discharge Coordinated discharge Patients will receive support by discharge coordinator for activities associated with discharge and immediate post-discharge care.
- Primary Outcome Measures
Name Time Method Number of patients hospitalized due to COPD worsening 180 days A hospitalization is defined as an unplanned overnight stay in hospital (different date for admission and discharge) due to acute worsening of COPD. Endpoint will be adjudicated by Endpoint committee.
- Secondary Outcome Measures
Name Time Method All-cause mortality 180 days Mortality will be ascertained at the Central Population Registry.
Health care costs 180 days Endpoint will be adjudicated by Endpoint committee.
Time to hospitalization due to COPD worsening 180 days A hospitalization is defined as an unplanned overnight stay in hospital (different date for admission and discharge) due to acute worsening of COPD. Endpoint will be adjudicated by Endpoint committee.
Days alive and out of hospital 180 days Endpoint will be adjudicated by Endpoint committee.
Health-related quality of life 180 days Endpoint will be adjudicated by Endpoint committee.
Acute exacerbations of COPD 180 days Endpoint will be adjudicated by Endpoint committee.
Trial Locations
- Locations (1)
University Clinic Golnik
🇸🇮Golnik, Slovenia